Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 2
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N. Dorward J, et al. Among authors: van der molen j. Lancet HIV. 2023 May;10(5):e284-e294. doi: 10.1016/S2352-3018(23)00047-4. Epub 2023 Mar 28. Lancet HIV. 2023. PMID: 37001536 Free PMC article.
Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
Asare K, Lewis L, van der Molen J, Sookrajh Y, Khubone T, Moodley P, Lessells RJ, Naidoo K, Sosibo P, Garrett N, Dorward J. Asare K, et al. Among authors: van der molen j. Open Forum Infect Dis. 2023 Nov 16;10(12):ofad583. doi: 10.1093/ofid/ofad583. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38045558 Free PMC article.
Clinical outcomes after extended 12-month antiretroviral therapy prescriptions in a community-based differentiated HIV service delivery programme in South Africa: a retrospective cohort study.
Lewis L, Sookrajh Y, van der Molen J, Khubone T, Sosibo P, Maraj M, van Heerden R, Little F, Kassanjee R, Garrett N, Dorward J. Lewis L, et al. Among authors: van der molen j. J Int AIDS Soc. 2023 Sep;26(9):e26164. doi: 10.1002/jia2.26164. J Int AIDS Soc. 2023. PMID: 37767825 Free PMC article.
Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study.
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J. Asare K, et al. Among authors: van der molen j. medRxiv [Preprint]. 2023 Jul 8:2023.07.07.23292347. doi: 10.1101/2023.07.07.23292347. medRxiv. 2023. PMID: 37461582 Free PMC article. Preprint.
Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
Asare K, Sookrajh Y, van der Molen J, Khubone T, Lewis L, Lessells RJ, Naidoo K, Sosibo P, van Heerden R, Garrett N, Dorward J. Asare K, et al. Among authors: van der molen j. Lancet Glob Health. 2024 Feb;12(2):e282-e291. doi: 10.1016/S2214-109X(23)00516-8. Epub 2023 Dec 21. Lancet Glob Health. 2024. PMID: 38142692 Free PMC article.